<DOC>
	<DOCNO>NCT01338974</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer treat cytarabine laboratory may help doctor learn effect cytarabine cell . It may also help doctor understand well patient respond treatment . PURPOSE : This research trial study biomarkers associate response cytarabine sample old patient acute myeloid leukemia .</brief_summary>
	<brief_title>S9031-S9333-S0112-S0301-A Biomarkers Associated With Response Cytarabine Samples From Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Refinement test multiparameter flow cytometry-based cell-signaling signature ( FC classifier ) associate vivo likelihood complete response ( CR ) cytarabine-based induction chemotherapy elderly patient ( 56 year old ) newly diagnose non-M3 acute myeloid leukemia ( AML ) . - Identification cell-signaling signature ( ) associate continuous CR cytarabine-based induction chemotherapy one year ( CCR1 ) adult patient 56 year old newly diagnose non-M3 AML . - Identification cell-signaling signature ( ) associate relapse-free survival one year ( RFS1 ) adult patient 56 year old newly diagnose non-M3 AML receive cytarabine-based induction chemotherapy achieve CR . - To investigate change cell-signaling signature ( ) match pre- post-treatment specimen relapsed/refractory patient . OUTLINE : This multicenter study . Cryopreserved specimens incubate cytokine ( e.g. , interleukin ) , growth factor ( e.g. , sargramostim filgrastim ) , chemotherapeutic agent ( e.g. , cytarabine , etoposide ) modulators . Cells fix , permeabilized , stained antibody recognize extracellular marker ( example , surface phenotypic marker cluster differentiation , drug transporter , receptor ) conjunction intracellular activation-state-specific epitope designate signal molecule . Subsequently , cell analyze phospho-flow cytometry ( FC ) random manner ( without knowledge clinical variable outcomes ) training set ( complete pre-specified FC ) versus test set . Cells also analyze proteomic assay . Results compare individual patient score , include predict clinical outcome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose nonM3 acute myeloid leukemia ( AML ) Pretreatment relapse/refractory cryopreserved marrow circulate mononuclear cell ( MC ) patient meet follow criterion : Eligible evaluable patient study SWOG9031 , SWOG9333 ( AraC/DNR induction arm ) , SWOGS0112 , SWOGS0301 Did refuse consent use specimen Have 2+ vial pretreatment marrow cell and/or 2+ vial pretreatment peripheral blood cell Southwest Oncology Group ( SWOG ) AML/MDS Repository PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>